Skip to main content
Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1

Fig. 1

Histopathologic and immunophenotypic studies of ipilimumab-induced Grover’s disease. a-c Scanning magnification of skin with acantholytic dyskeratosis (a, H&E, 20×). Higher magnification reveals skin with suprabasal acantholysis and overlying dyskeratosis; (b, H&E, 100×) and (c, H&E, 40×). Immunohistochemical studies demonstrate a predominance of CD3+ T-cells (d, anti-CD3, 100×) comprised of a predominance of CD4+ T-cells (e, anti-CD4, 100×) over CD8+ T-cells (f, anti-CD8, 100×). Additional immunohistochemical studies demonstrate strong expression of PD-L1 by the inflammatory cells (g, anti-PD-L1, 100×; inset, 400×). Scattered cells express PD-1 (h, anti-PD-1, 100×; inset 400×). There is scattered nuclear expression of FoxP3 (i, anti-FoxP3, 100×; inset 400×) and T-beta (j, anti-T-Bet, 100×; inset, 400×) but strong diffuse nuclear expression of Gata-3 by the majority of the inflammatory cells as well as the overlying keratinocytes (k, anti-Gata-3, 100×; inset: 400×). Antibodies for RORgT are essentially negative in the infiltrate. There is strong background staining in the skin tissue (l, anti-RORgT, 100×; inset: 400×)

Back to article page